Illumina, Inc.
ILMN Healthcare Diagnostics & Research
Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue grew 9.44%, EPS fell 8.05%, free cash flow fell 18.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow ILMN
Illumina, Inc. (ILMN) Return on assets
Illumina, Inc.'s return on assets over the twelve months to 30 June 2026 was 13.0%, down 0.2 percentage points from fiscal 2025 (13.1%). Over the past ten years it has ranged from −32.1% (fiscal 2022) to 15.2% (fiscal 2017); the current reading is higher than 64% of that period. That is above the Diagnostics & Research industry median of −6.71% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 13.1% | 28.03 |
| FY2024 | −14.9% | (4.52) |
| FY2023 | −10.4% | 21.69 |
| FY2022 | −32.1% | (38.75) |
| FY2021 | 6.68% | (2.12) |
| FY2020 | 8.80% | (5.24) |
| FY2019 | 14.0% | 0.52 |
| FY2018 | 13.5% | (1.70) |
| FY2017 | 15.2% | 3.60 |
| FY2016 | 11.6% | (1.53) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 33.7% |
| MTD Mettler-Toledo International, Inc. compare | 25.6% |
| ILMN Illumina, Inc. | 13.0% |
| A Agilent Technologies, Inc. compare | 11.0% |
| DGX Quest Diagnostics Incorporated compare | 6.43% |
| LH Labcorp Holdings Inc. compare | 5.48% |
| IQV IQVIA Holdings Inc. compare | 4.70% |
| WAT Waters Corporation compare | 1.13% |
| NTRA Natera, Inc. compare | −8.71% |
| Diagnostics & Research industry median | −6.71% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ILMN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement